Boston Research Partnership Studies Skin Microbiome Potential

A new three-year collaboration aims to uncover how microbiome-derived ingredients could support skin and metabolic health.

Updated on Oct. 21, 2026 in Beauty

Boston Research Partnership Studies Skin Microbiome Potential

Live Poll

Do you believe medical research partnerships between hospitals and companies improve the health products you use?

COSMAX and Mass General Brigham have launched a multi-year research partnership, known as the VIVA Project, to study the skin microbiome. This collaboration aims to identify functional ingredients for anti-aging and metabolic health through AI-driven analysis.

Why it matters

By merging microbiome data with clinical health records, researchers hope to create advanced materials that could eventually influence how we manage skin barrier health and metabolic processes. The partnership marks a formal expansion of initial research that already identified specific microorganism-derived substances linked to atopic dermatitis relief.

Initial phase findings published in the journal Allergy identified microorganism-derived substances that alleviate atopic dermatitis and improve skin barrier function. The broader clinical potential of these findings is still under investigation, as current research enters a new phase.

The players

COSMAX

A research and development company focused on cosmetics and microbiome-based functional ingredients.

Mass General Brigham

A Boston-based academic medical center and health care system that conducts clinical research and medical education.

The details

The VIVA Project integrates COSMAX skin microbiome datasets with Massachusetts General Brigham clinical data to identify novel functional materials. Scientists are employing AI-based analysis to build hypotheses and optimize candidates for health applications. This approach seeks to isolate specific lactic acid bacteria and functional ingredients that may offer benefits similar to current GLP-1 treatments.

The first phase of basic and translational research began in 2024.
The official research agreement was signed on October 21, 2026.
The VIVA Project is scheduled to continue from 2026 to 2029.

Health Landscape

This initiative follows a pattern established by the human microbiome research initiative, moving from observational study to target-based therapeutic development. It represents an increasing focus on integrating AI-driven data analysis into the search for next-generation skin and metabolic therapies.

While these developments are currently in the research phase, they underscore the evolving science behind microbiome-based skin care. If you are managing chronic skin conditions like atopic dermatitis, keep an eye on clinical trial announcements and discuss emerging evidence-based treatments with your dermatologist.

The takeaway

The study of the skin microbiome is moving toward more targeted, AI-validated ingredients that may eventually support skin barrier and metabolic health. As this research progresses, continue to rely on proven skin-care habits and consult your physician regarding the best treatments for your specific skin concerns.